Although the clinical utilization for such treatment remains to be determined, YAP1 as a biomarker may aid in the individual prognostication of patients diagnosed with pancreatic cancer and the selection of precision therapy. This evidence concerns the gene YAP1 and familial pancreatic carcinoma.